Pfizer (PFE) Stock Rebounds on Trump Drug Deal & Obesity Gamble – Can the Rally Last?
PFE Stock Price and Recent Performance Pfizer’s stock has endured a rough 2025, trading in the low-to-mid $20s for much of the year and touching multi-year lows. By late September, PFE was around $23.60 – down ~9% year-to-date and ~18% from a year prior ts2.tech. It languished near the bottom of its 52-week range ($20.92 – $30.43) ts2.tech as the company faced a post-pandemic hangover: revenues from its COVID-19 vaccine (Comirnaty) and pill (Paxlovid) plummeted from $37.8B in 2022 to about $12.5B in 2024 ts2.tech. Wall Street projected Pfizer’s EPS would fall by more than half from 2022 to 2025
